Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination.
Journal Article (Journal Article)
Recently approved vaccines have shown remarkable efficacy in limiting SARS-CoV-2-associated disease. However, with the variety of vaccines, immunization strategies, and waning antibody titers, defining the correlates of immunity across a spectrum of antibody titers is urgently required. Thus, we profiled the humoral immune response in a cohort of non-human primates immunized with a recombinant SARS-CoV-2 spike glycoprotein (NVX-CoV2373) at two doses, administered as a single- or two-dose regimen. Both antigen dose and boosting significantly altered neutralization titers and Fc-effector profiles, driving unique vaccine-induced antibody fingerprints. Combined differences in antibody effector functions and neutralization were associated with distinct levels of protection in the upper and lower respiratory tract. Moreover, NVX-CoV2373 elicited antibodies that functionally targeted emerging SARS-CoV-2 variants. Collectively, the data presented here suggest that a single dose may prevent disease via combined Fc/Fab functions but that two doses may be essential to block further transmission of SARS-CoV-2 and emerging variants.
- Gorman, MJ; Patel, N; Guebre-Xabier, M; Zhu, AL; Atyeo, C; Pullen, KM; Loos, C; Goez-Gazi, Y; Carrion, R; Tian, J-H; Yuan, D; Bowman, KA; Zhou, B; Maciejewski, S; McGrath, ME; Logue, J; Frieman, MB; Montefiori, D; Mann, C; Schendel, S; Amanat, F; Krammer, F; Saphire, EO; Lauffenburger, DA; Greene, AM; Portnoff, AD; Massare, MJ; Ellingsworth, L; Glenn, G; Smith, G; Alter, G
- September 21, 2021
Volume / Issue
- 2 / 9
Start / End Page
- 100405 -
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)
- United States